AACR 2025 Recap: Immunotherapy Shifts, ctDNA Surveillance, and Breakthroughs in HER2 and AML

In this post-conference episode, Mike breaks down five major stories from AACR 2025:KEYNOTE-689 trial changes the standard of care in head and neck cancerZongertinib delivers HER2-targeted efficacy with fewer side effects in lung cancerCAR NK cells show durable remission in AMLctDNA testing in CRC detects recurrence 6+ months before imagingWerner helicase inhibitor shows first-in-class potential in MSI tumorsListen in for a concise roundup of the data and why it matters.